ArticleCellular oncology (Dordrecht, Netherlands)2025
Mendelian analysis reveals novel pancreatic cancer-associated gut bacteria with tumor-suppressive effects.
Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe gut microbiota has been implicated in the development and progression of pancreatic cancer (PC), yet few specific bacterial species have been reported to exert functional effect on PC. This study aimed to identify novel PC-associated gut bacterial species with tumor-regulatory effects and explore the potential molecular mediators of their effect.
methodsA bidirectional two-sample mendelian randomization (MR) analysis was performed using summary statistics from the MiBioGen consortium (n = 18,340) for gut microbiota and from the GWAS Catalog (587 PC cases, 455,761 controls) to assess their causal relationship. A two-step MR analysis incorporating blood metabolite data (n = 8,299 from the GWAS Catalog) was conducted to investigate potential mediation via circulating metabolites. Functional validation of identified bacterial taxa was carried out in murine models of PC via oral gavage of representative species.
resultsSix bacterial taxa, including four genera, demonstrated reliable evidence of causal associations with PC. Eggerthella and Parasutterella were identified as protective for PC, whereas Sutterella and Coprococcus1 were associated with increased PC risk. Additionally, 26 blood metabolites showed causal associations with PC. After evaluating the causal relationships between PC-associated gut microbiota and blood metabolites, we found that the Eggerthella genus and Sutterella genus exert causal effect on PC by reducing the circulating levels of deoxycarnitine and hypotaurine, respectively. In two distinct orthotopic PC models, oral administration of Eggerthella lenta (E. lenta, the type species of the Eggerthella genus) or Parasutterella excrementihominis (P. excrementihominis, the type species of the Parasutterella genus) consistently exerted significant tumor-suppressive effects on the growth of pancreatic tumors. Moreover, E. lenta administration enhanced the infiltration of CD8⁺ T cells and NKT cells within orthotopic pancreatic tumors, suggesting a potential role of E. lenta in reshaping the tumor immune microenvironment to favor antitumor immunity.
conclusionsThis study identifies E. lenta and P. excrementihominis as novel PC-associated gut bacterial species with tumor-suppressive effects, offering potential candidates for probiotic-based interventions in PC. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.